Clinical Trials Logo

Carcinoma, Ovarian Epithelial clinical trials

View clinical trials related to Carcinoma, Ovarian Epithelial.

Filter by:

NCT ID: NCT05431530 Recruiting - Ovarian Cancer Clinical Trials

Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer

Start date: June 22, 2022
Study type: Observational

This study aims to evaluate the incidence of low anterior resection syndrome and quality of life after cytoreductive surgery for advanced ovarian cancer patients.

NCT ID: NCT05430906 Not yet recruiting - Ovarian Cancer Clinical Trials

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Start date: July 2022
Phase: Phase 2
Study type: Interventional

Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile. AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to evaluate the efficacy and safety of AK104 combined with chemotherapy as the neoadjuvant treatment for advanced ovarian cancer.

NCT ID: NCT05429970 Recruiting - Ovarian Cancer Clinical Trials

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

NCT ID: NCT05422183 Not yet recruiting - Clinical trials for Ovarian Cancer, Epithelial

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer´╝îprimary fallopian tube cancer and primary peritoneal carcinoma.

NCT ID: NCT05415709 Recruiting - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Start date: July 1, 2022
Phase: Early Phase 1
Study type: Interventional

This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial chemotherapy involves the infusion of heated cytotoxic chemotherapy that circulates into the abdominal cavity at the time of surgery. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery may kill more tumor cells compared to usual care.

NCT ID: NCT05415527 Not yet recruiting - Ovarian Carcinoma Clinical Trials

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

Start date: June 10, 2022
Phase: N/A
Study type: Interventional

Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.

NCT ID: NCT05410938 Recruiting - Clinical trials for Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer

Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Start date: June 6, 2022
Study type: Observational

The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.

NCT ID: NCT05410028 Recruiting - Ovarian Cancer Clinical Trials

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

Start date: March 3, 2022
Study type: Observational

In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.

NCT ID: NCT05410015 Recruiting - Ovarian Cancer Clinical Trials

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

Start date: February 3, 2022
Study type: Observational

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

NCT ID: NCT05406674 Not yet recruiting - Peritoneal Cancer Clinical Trials

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer

Start date: June 2022
Phase: Phase 2
Study type: Interventional

Cytoreductive surgery (CRS) with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is used in current clinical practice in selected patients with advanced ovarian cancer. Clinical evidence for the benefit of HIPEC in ovarian cancer comes from the pivotal phase 3 OVHIPEC trial. Worldwide, two established strategies exist for dosing of HIPEC protocols, which follow either a body surface area (BSA)-based or a concentration-based approach. Since both strategies result in different exposure to intra-peritoneal chemotherapy, we aim to compare the pharmacokinetics and safety of both strategies.